The National Institute of Nanotechnology and Defence Research and Development Canada will study the Chimigen™ Vaccine platform.
ViRexx Medical inked deals with the Canada’s National Research Council National Institute for Nanotechnology (NRC-NINT) and Defence Research and Development Canada (DRDC) Suffield.
“These research collaborations were supported through network and financial contributions from NRC-IRAP (Industrial Research Assistance Program), which provide us with the opportunity to explore multiple uses of our Chimigen Vaccine platform technology and establish its efficacy as an adaptable platform technology in nanoparticle and biodefence applications,” comments Peter Smetek, interim CEO and chairman of the board of directors of ViRexx Medical.
Researchers at NINT will investigate the physical characteristics and immunological and nanoparticle forming properties of the company’s Chimigen™ vaccine. Scientists at DRDC Suffield will continue to study the Chimigen Vaccine platform for biodefense applications.
